Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer
Conditions: BRAF NP_004324.2:p.V600M; BRAF V600E Mutation Present; Metastatic Thyroid Gland Carcinoma; Refractory Thyroid Gland Carcinoma; Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8; Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8; Stage IVB Differentiated T hyroid Gland Carcinoma AJCC v8 Interventions: Drug: Binimetinib; Drug: Encorafenib; Biological: Nivolumab Sponsors: OHSU Knight Cancer Institute; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials